[Rituximab for patients with diagnosed chronic neuromyelitis, myasthenia gravis and chronic inflammatory demyelinating polyneuropathy]

Molinari L; García Martí S; Pichon-Riviere A, Augustovski F, Alcaraz A, Bardach A, Ciapponi A.
Record ID 32018001501
Spanish
Original Title: Rituximab en pacientes con diagnóstico de neuromielitis óptica, miastenia gravis y polineuropatía desmielinizante inflamatoria crónica
Authors' recomendations: CONCLUSIONS Low-quality evidence suggests that rituximab in patients with neuromyelitis optic or neuromyelitis optic spectrum disorders would decrease the incidence of relapse in patients treated with standard treatments. Low-quality evidence suggests that rituximab in patients with myasthenia gravis would show improvement in clinical symptoms and disease exacerbations in patients treated with standard treatments. Low-quality evidence suggests that rituximab in patients with chronic inflammatory demyelinating polyneuropathy would decrease disease progression. The clinical practice guidelines consulted recommend its use for patients with optic neuromyelitis or its spectrum disorders and in patients with refractory myasthenia gravis, or with low response to standard treatments. In the case of refractory chronic inflammatory demyelinating polyneuropathy, the guide of the Mexican Academy of Neurology recommends it for those cases related to blood disorders and the European Federation of Neurological Diseases does not recommend it in any case. Rituximab has not been authorized by ANMAT, the FDA or EMA for any of these indications. Most Latin-American public health sponsors and those from high-income countries do not mention it or do not provide coverage for these indications; only two United States private sponsors cover it for optic neuromyelitis or its spectrum disorders.
Details
Project Status: Completed
Year Published: 2018
URL for published report: https://www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Neuromyelitis Optica
  • Myasthenia Gravis
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
  • Rituximab
  • Drug Therapy
Contact
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.